# Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

> **NCT03110640** · PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 20 (estimated)

## Conditions studied

- B-cell Adult Acute Lymphoblastic Leukemia
- B-cell Chronic Lymphocytic Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Hematopoietic/Lymphoid Cancer
- Refractory Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** anti-CD19 CAR-T
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03110640
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10-01
- **Primary completion:** 2020-06
- **Final completion:** 2021-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-11-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03110640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03110640, "Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03110640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*